[Actinic prurigo. Treatment with antifibribolytics].
Preceded by a brief commentary about the clinical characteristics of actinic prurigo, the qualities of anantifibrinolytic medication and its possible machanism of action in allergic conditions and atopias are analysed. An earlier experience with five familiar cases of actinic prurigo given 1 g of tranexamic acid or 3 g E. ACA, within a period of three months has been effective remarkally exceeding the results obtained with other therapeutic agents. The proposed therapeutic scheme may or may not be, modified, according to the response to the response of each individual case.
D000293:Adolescent; D000328:Adult; D015119:Aminocaproic Acid / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000235:genetics; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005148:Facial Dermatoses / Q000188:drug therapy / Q000209:etiology* / Q000235:genetics; D005260:Female; D006801:Humans; D008297:Male; D011536:Prurigo / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics; D013472:Sunlight; D014148:Tranexamic Acid / Q000627:therapeutic use
D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid; D015119:Aminocaproic Acid
Prurigo actínico. Tratamiento con antifibrinoliticos.